Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease-Reference-Cited by-同舟云学术

Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease

Published:2020-05-12 Issue:9 Volume:4 Page:2058-2063
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Hsieh Matthew M.¹^ORCID,Bonner Melissa²,Pierciey Francis John²,Uchida Naoya¹^ORCID,Rottman James²,Demopoulos Laura²,Schmidt Manfred³,Kanter Julie⁴^ORCID,Walters Mark C.⁵^ORCID,Thompson Alexis A.⁶⁷^ORCID,Asmal Mohammed²,Tisdale John F.¹^ORCID

Affiliation:

1. Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;

2. bluebird bio, Inc, Cambridge, MA;

3. GeneWerk GmbH, Heidelberg, Germany;

4. Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL;

5. University of California San Francisco Benioff Children’s Hospital, Oakland, CA;

6. Division of Hematology, Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL; and

7. Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL

Abstract

Key Points Ability to accurately attribute adverse events post–gene therapy is required to describe the benefit-risk of these novel treatments. A SCD patient developed myelodysplastic syndrome post-LentiGlobin treatment; we show how insertional oncogenesis was excluded as the cause.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/4/9/2058/1728701/advancesadv2019001330.pdf

Reference32 articles.

1. Gene therapy of the β-hemoglobinopathies by lentiviral transfer of the β(A(T87Q))-globin gene;Negre;Hum Gene Ther,2016

2. Gene therapy in a patient with sickle cell disease;Ribeil;N Engl J Med,2017

3. The incidence of secondary leukemias;Leone;Haematologica,1999

4. Acute lymphoblastic leukaemia occurring as second malignancy: report of the GIMEMA archive of adult acute leukaemia. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto;Pagano;Br J Haematol,1999

5. Treating immunodeficiency through HSC gene therapy;Booth;Trends Mol Med,2016

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fostering a healthier generation of children with sickle cell disease through advancements in care;Pediatric Research;2024-09-13

2. The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?;International Journal of Molecular Sciences;2024-09-01

3. Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel) for individuals 12 years and older with sickle cell disease (SCD) and recurrent vaso-occlusive crises (VOC): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG);Genetics in Medicine Open;2024-09

4. The Role of the Conditioning Regimen for Autologous and Ex Vivo Genetically Modified Hematopoietic Stem Cell-based Therapies: Recommendations from the ISCT Stem Cell Engineering Committee;Cytotherapy;2024-09

5. Current and emerging drug treatment strategies to tackle sickle cell anemia;Expert Opinion on Emerging Drugs;2024-07-22